BLRD Merit Review Research Career Scientist Award

BLRD 优异评审研究职业科学家奖

• 批准号: 10594022
• 负责人: Shyam S Mohapatra
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2029-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10594022
• 关键词: 2019-nCoV; 3-Dimensional; Acceleration; Affect; American; Anti-Inflammatory Agents; Artificial Intelligence; Asthma; Award; Biological Assay; Biology; Biopsy; Birds; CCL20 gene; COVID-19; Cell Therapy; Cells; Clinical; Clinical Trials; Collaborations; Data; Development; Diagnostic; Disease; Education; Educational process of instructing; Elderly; Endowment; Extramural Activities; Florida; Formulation; Funding; Future; General Population; Goals; Health; Healthcare; Hospitals; Hypersensitivity; Image Enhancement; Immunocompetent; Immunology; In Vitro; Incidence; Individual; Industry Collaboration; Inflammation; Inflammatory; International; Investments; Lead; Legal patent; Liposomes; Malignant neoplasm of brain; Malignant neoplasm of lung; Medicine; Mesenchymal Stem Cells; Methods; Modeling; Mus; Nanofiber Scaffold; Nature; Nerve Regeneration; Nursing Faculty; Oligosaccharides; Oncolytic; Peptides; Phospholipids; Pneumonia; Property; Prophylactic treatment; Publications; Reporting; Research; Research Activity; Research Personnel; Research Support; Respiratory Syncytial Virus Infections; Respiratory syncytial virus; SARS-CoV-2 antiviral; Safety; Scientist; Seminal; Small Interfering RNA; System; Technology; Testing; Therapeutic; Translations; Traumatic Brain Injury; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Veterans; Viral; Viral Respiratory Tract Infection; Virus Diseases; Work; bench to bedside; career; chest computed tomography; clinical diagnosis; clinical diagnostics; clinical training; combinatorial; drug efficacy; efficacy testing; experience; graduate student; human disease; improved; in vivo; indexing; influenza infection; inhibitor; innovation; mouse model; nano; nanoformulation; nanomedicine; nanomicelles; nanoscale; nanosystems; nanotherapeutic; novel; novel diagnostics; novel therapeutics; novel virus; pandemic disease; particle; personalized cancer therapy; prevent; professor; prophylactic; respiratory infection virus; stem cell therapy; translational medicine

This proposal seeks to renew Research Career Scientist Award held by Dr. Shyam S Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2007. He is a Distinguished Health Professor and the Director of the Division of Translational Medicine- Center for Research and Education in Nanobioengineering at the VA-affiliated academic center- the University of South Florida. With ~235 publications, 40 patents, an h-index of 53 and an i-index of 161, he is recognized nationally and internationally for his contributions to the field of nanoscale biomedical diagnostics and therapeutics in relation to viral infections, traumatic brain injury (TBI) and cancers. He has received substantial extramural research support including awards from the NIH, DOA, ONR, Department of Veterans’ Affairs and Florida Department of Health. He is the recipient of several international/national awards and recognitions. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 1996 and has been continuously funded with the Merit Review Award focused on respiratory syncytial virus (RSV) infection since 1999. Current and ongoing research activities to be supported by this RCS Award are as follows. Project #1. a) Develop new prophylactic, or therapeutic approaches involving broad antiviral and anti-inflammatory compounds formulated using novel nanoscale technologies, which are effective against COVID-19 and other respiratory viral infections. The currently proposed Merit Review project aims to develop a simple, smart and translatable nanoscale system that combines novel targets for antiviral- and replication and inflammation inhibitors. He currently leads two additional projects, as a multi-PI. This proposal aims to characterize novel virus-neutralizing particles that may serve as prophylaxis and/or therapy. b) Also, based on his recent experience in artificial intelligence (AI)-enhanced imaging, and preliminary data with COVID-19, he was funded by CSRD to examine the potential to clinically diagnose and prognose COVID 19 by AI-aided chest CT. Project #2. Investigate and test a novel targeted oncolytic viro-cell therapy (OVT) for lung cancer using the mesenchymal stem cell (MSCs) infected by RSV, which is harmless for immunocompetent individuals. Thus, it is planned to use a 3D multicell tumoroid and biopsy-derived cultures in vitro and mouse model of lung cancer in vivo to evaluate the safety and efficacy of OVT. The project to data has attracted industry collaboration, which might lead to clinical trials. Project #3. Investigate the potential of a novel combinatorial therapeutic approach in a mouse CCI model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by MSC therapy. VA Impact: These highly innovative applications of nanomedicine approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic, and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. The development of these effective nanotherapeutics will greatly improve the quality of Veteran’s healthcare.

该提案旨在更新Shyam S Mohapatra博士持有的研究职业科学家奖， 詹姆斯A。自2007年以来，在佛罗里达的坦帕的Haley VA医院。他是一个杰出的健康 教授和转化医学部主任-研究中心和 在VA附属学术中心的纳米生物工程教育-南大学 佛罗里达。他拥有约235篇出版物，40项专利，h指数为53，i指数为161， 在国内和国际上对纳米生物医学诊断领域的贡献 以及与病毒感染、创伤性脑损伤（TBI）和癌症相关的治疗剂。他 获得了大量的校外研究支持，包括NIH，DOA，ONR， 退伍军人事务部和佛罗里达卫生部。他是几个接受者 国际/国内奖项和荣誉。莫哈帕特拉博士一直是一名研究调查员， 自1996年以来，VA医院（医学）一直获得Merit Review的资助 自1999年以来，该奖项专注于呼吸道合胞病毒（RSV）感染。目前和正在进行的 本研究中心奖资助的研究活动如下。 一号工程。a）开发新的预防或治疗方法，包括广泛的抗病毒药物， 以及使用新的纳米级技术配制的抗炎化合物， 有效对抗COVID-19和其他呼吸道病毒感染。目前提出的优点 审查项目旨在开发一个简单，智能和可翻译的纳米系统， 抗病毒、复制和炎症抑制剂的新靶点。他目前领导着两个 更多的项目，作为一个多PI。该提案旨在表征新型病毒中和颗粒 其可以用作预防和/或治疗。B）此外，根据他最近在人工 智能（AI）增强成像和COVID-19的初步数据，他由CSRD资助 通过人工智能辅助胸部CT检查临床诊断和预防COVID 19的潜力。 二号工程。研究和测试一种新的靶向溶瘤病毒细胞治疗（OVT）， 使用RSV感染的间充质干细胞（MSC）的癌症， 免疫活性个体。因此，计划使用3D多细胞类瘤和活检衍生的 体外培养和小鼠体内肺癌模型评价OVT的安全性和有效性。 数据项目吸引了行业合作，这可能导致临床试验。 第三个项目。研究一种新的组合治疗方法的潜力， 中度TBI的小鼠CCI模型，其包括（i）减少炎症（局部和局部）的治疗， 系统性）使用针对最近发现的靶标CCL 20的纳米配制的siRNA，和（ii） 第二次治疗通过MSC疗法促进神经再生。 VA影响：这些高度创新的纳米医学方法的应用 预计将为退伍军人提供高影响力的临床诊断和治疗， 其他需要帮助的美国人退伍军人受到大流行病的影响， 与一般人群相比，受肺癌和TBI发病率的影响越来越大。 这些有效的纳米治疗药物的开发将大大提高退伍军人的质量 健康护理